Zacks.com on MSN
Biotech ETFs Hovering Around a 52-Week: Here's Why
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the ...
Stocks to Buy and Sell. Biotechnology ETF (NASDAQ:IBB) is one of the trending analyst calls. Jason Snipe, Founder and CIO of ...
Fintel reports that on October 30, 2025, Raymond James reiterated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a ...
Fintel reports that on October 30, 2025, Piper Sandler maintained coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a ...
Bluehill Capital, SOSV, and other global investors participated in the round. The Hyderabad- and US-based biotech startup ...
Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about ...
Biotech company Pila Pharma has recently completed a strongly oversubscribed share issue on Nasdaq First North in Stockholm. The raised capital of nearly SEK 30 million will finance the first steps of ...
Key updates on Reliance, HDFC Bank, TCS, and more, highlighting strategic partnerships, order wins, and company developments ...
Vohra was the second executive roped in from outside Cipla’s promoter family to lead the drug maker. Under his watch, Cipla ...
Altimmune continues developing pemvidutide for MASH but has yet to secure a partner or acquisition despite sector M&A ...
Stockhead on MSN
Closing Bell: ASX staggers into weekend as Mayne gets mauled and gold comes back to life
Well, at least it wasn’t a total market massacre today – gold revived just in time to offset Mayne Pharma’s Halloween shocker ...
Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback